Impact of Recent Findings on Study Design of Future Autism Clinical Trials

Eric Hollander, Ann Phillips, Bryan H. King, Donald Guthrie, Michael G. Aman, Paul Law, Thomas Owley, Ricki Robinson

Research output: Contribution to journalReview article

20 Scopus citations

Abstract

There are specific challenges to studying the design of pharmacologic trials in child/adolescent and adult autism, such as subject stratification and parallel versus crossover designs. This article describes how optimal study design is influenced by subject selection and outcome measures chosen. Lessons learned in study design from the Research Units on Pediatric Psychopharmacology Autism Network trial with risperidone, Seaver Center trials with fluoxetine and valproate, Dartmouth trials with amantadine, and National Institutes of Health secretin trials are highlighted. The Internet System for Assessing Autistic Children system for managing multicenter clinical trials in autism and statistical issues in autism research are also described.

Original languageEnglish (US)
Pages (from-to)49-56
Number of pages8
JournalCNS spectrums
Volume9
Issue number1
DOIs
StatePublished - Jan 2004
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Hollander, E., Phillips, A., King, B. H., Guthrie, D., Aman, M. G., Law, P., Owley, T., & Robinson, R. (2004). Impact of Recent Findings on Study Design of Future Autism Clinical Trials. CNS spectrums, 9(1), 49-56. https://doi.org/10.1017/S109285290000835X